AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8482184 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 8
Study 8482184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3514488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 45
Study 3514488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 45
Study 30468408 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Aware program
Number of subjects: 880
Study 30468408 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control
Number of subjects: 880
Study 27595414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led management model (n=36)
Number of subjects: 73
Study 27595414 — intervention group
Group type: COMPARATOR
Intervention: Doctor-led management model (n=37)
Number of subjects: 73
Study 24050682 — intervention group
Group type: EXPERIMENTAL
Intervention: Body armour (loaded)
Number of subjects: 52
Study 24050682 — intervention group
Group type: EXPERIMENTAL
Intervention: Distracted drop landing
Number of subjects: 52
Study 24050682 — intervention group
Group type: COMPARATOR
Intervention: Unloaded (control)
Number of subjects: 52
Study 22875553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Program (IP)
Number of subjects: 1416
Study 22875553 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Program (RP)
Number of subjects: 1416
Study 22875553 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A intake from OSP
Number of subjects: 1416
Study 20175283 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine (Group L, n = 30)
Number of subjects: 60
Study 20175283 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (Group B, n = 30)
Number of subjects: 60
Study 17971487 — intervention group
Group type: EXPERIMENTAL
Intervention: R-DHAP (rituximab + DHAP chemotherapy)
Number of subjects: 225
Study 17971487 — intervention group
Group type: COMPARATOR
Intervention: DHAP (chemotherapy without rituximab)
Number of subjects: 225
Study 17971487 — intervention group
Group type: EXPERIMENTAL
Intervention: R-DHAP
Number of subjects: 225
Study 17971487 — intervention group
Group type: COMPARATOR
Intervention: DHAP
Number of subjects: 225
Study 15948814 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole (bedtime dosing)
Number of subjects: 36
Study 15948814 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole (once daily predinner dosing)
Number of subjects: 36
Study 15948814 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole (twice daily prebreakfast and bedtime dosing)
Number of subjects: 36
Study 15948814 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole (twice daily dosing 20 and 40 mg)
Number of subjects: 36
Study 15948814 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole (40 mg bedtime dosing)
Number of subjects: 36
Study 15948814 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole (twice daily dosing 40 mg)
Number of subjects: 36
Study 12756503 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m tetrofosmin (TF) washout
Number of subjects: 31
Study 12756503 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 31
Study 12756503 — intervention group
Group type: EXPERIMENTAL
Intervention: TF washout
Number of subjects: 31
Study 12756503 — intervention group
Group type: EXPERIMENTAL
Intervention: TF uptake
Number of subjects: 31
Study 10368917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program designed to enhance mother-infant interaction
Number of subjects: 36
Study 10368917 — intervention group
Group type: COMPARATOR
Intervention: Control group intervention emphasizing basic caregiving skills
Number of subjects: 36
Study 8678062 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant citrate dextrose-A (ACD) (0.113 mol/L citrate)
Number of subjects: 8
Study 8678062 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic tri-sodium citrate (TSC) (1.6 mol/L citrate)
Number of subjects: 8
Study 1762669 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming effects in amnesic patients
Number of subjects: 9
Study 1762669 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming effects in young subjects
Number of subjects: 9
Study 1762669 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming effects in age-matched control subjects
Number of subjects: 9
Study 1762669 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of words in amnesic patients
Number of subjects: 9
Study 6401229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (TNG)
Number of subjects: 40
Study 6401229 — intervention group
Group type: COMPARATOR
Intervention: Oral isosorbide dinitrate (ISDN) and topical 2% nitroglycerin ointment (NO)
Number of subjects: 40
Study 31624854 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dialysis catheters (DC)
Number of subjects: 3029
Study 31624854 — intervention group
Group type: COMPARATOR
Intervention: Central venous catheters (CVC)
Number of subjects: 3029
Study 28234775 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple randomization
Number of subjects: 0
Study 28234775 — intervention group
Group type: EXPERIMENTAL
Intervention: Block randomization
Number of subjects: 0
Study 28234775 — intervention group
Group type: EXPERIMENTAL
Intervention: Techniques to account for confounding variables
Number of subjects: 0
Study 26830377 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy (craniospinal irradiation of 18-36 GyRBE delivered at 1.8 GyRBE per fraction)
Number of subjects: 59
Study 26830377 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Number of subjects: 59
Study 24174275 — intervention group
Group type: EXPERIMENTAL
Intervention: landiolol hydrochloride 0.125 mg/kg
Number of subjects: 258
Study 24174275 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 258
Study 22770832 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness to change behavior for 2 daily servings of milk
Number of subjects: 75
Study 22770832 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness to change behavior for 4 daily servings of milk
Number of subjects: 75
Study 19582636 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI chart prompt in electronic medical record
Number of subjects: 846
Study 19582636 — intervention group
Group type: COMPARATOR
Intervention: No BMI chart prompt in electronic medical record
Number of subjects: 846
Study 19582636 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity comorbidities (specifically obstructive sleep apnea)
Number of subjects: 846
Study 17505300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen delivery (DO2)
Number of subjects: 69
Study 17505300 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous pressure of oxygen (PtcO2)
Number of subjects: 69
Study 17505300 — intervention group
Group type: EXPERIMENTAL
Intervention: PtcO2 goal at 24 h after resuscitation (T24)
Number of subjects: 69
Study 17505300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen challenge test (OCT)
Number of subjects: 69
Study 16243988 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 0.1 mg plus Dexamethasone 8 mg (G+D)
Number of subjects: 176
Study 16243988 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg plus Dexamethasone 8 mg (O+D)
Number of subjects: 176
Study 12195324 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless capsule endoscopy (CE)
Number of subjects: 65
Study 12195324 — intervention group
Group type: COMPARATOR
Intervention: Push enteroscopy (PE)
Number of subjects: 65
Study 9842758 — intervention group
Group type: EXPERIMENTAL
Intervention: High-visual complexity pictures
Number of subjects: 6
Study 9842758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-visual complexity pictures
Number of subjects: 6
Study 9842758 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 6
Study 7988580 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 8
Study 7988580 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 8
Study 7988580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2648657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 301
Study 2648657 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 301
Study 2648657 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 301
Study 29553033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (12.9 mmol nitrate)
Number of subjects: 20
Study 29553033 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (0.5 mmol nitrate)
Number of subjects: 20
Study 29084686 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 120
Study 29084686 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besilate (Control)
Number of subjects: 120
Study 25979249 — intervention group
Group type: EXPERIMENTAL
Intervention: CadC with intact linker
Number of subjects: 0
Study 25979249 — intervention group
Group type: EXPERIMENTAL
Intervention: CadC with truncated linker
Number of subjects: 0
Study 25979249 — intervention group
Group type: EXPERIMENTAL
Intervention: CadC dimerization
Number of subjects: 0
Study 25979249 — intervention group
Group type: EXPERIMENTAL
Intervention: CadC variant lacking most of the linker
Number of subjects: 0
Study 23654110 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% L-arabinose
Number of subjects: 50
Study 23654110 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% L-arabinose
Number of subjects: 50
Study 23654110 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% L-arabinose
Number of subjects: 50
Study 23654110 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arabinose (daily for six months)
Number of subjects: 50
Study 23654110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21713377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine administration
Number of subjects: 192
Study 18718892 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (irinotecan 180 mg/m² on day 1 + 5-fluorouracil 400 mg/m² bolus and 600 mg/m² 22-h infusion + leucovorin 200 mg/m² on days 1-2, every 2 weeks)
Number of subjects: 346
Study 18718892 — intervention group
Group type: EXPERIMENTAL
Intervention: FUIRI (irinotecan 80 mg/m² + 5-fluorouracil 2,250 mg/m² 48-h infusion, weekly)
Number of subjects: 346
Study 18718892 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 346
Study 18718892 — intervention group
Group type: EXPERIMENTAL
Intervention: FUIRI
Number of subjects: 346
Study 17008196 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing targeted to smoking behaviors exclusively (smoking only)
Number of subjects: 46
Study 17008196 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing targeted to smoking and other addictions or life events (smoking plus)
Number of subjects: 46
Study 17008196 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (21 mg)
Number of subjects: 46
Study 17008196 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenges (4 mg)
Number of subjects: 46
Study 15273014 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of gender fairness of a math test
Number of subjects: 0
Study 11214850 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based Alcohol Early Intervention Education Package (AEIEP)
Number of subjects: 212
Study 9714485 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of aortic coarctation
Number of subjects: 44
Study 7978588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal midazolam (0.25 mg/kg)
Number of subjects: 58
Study 7978588 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 58
Study 2657523 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzocaine 20% gel
Number of subjects: 40
Study 2657523 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 40
Study 30797989 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Imagery condition (N = 24)
Number of subjects: 72
Study 30797989 — intervention group
Group type: COMPARATOR
Intervention: Activity Reminder control condition (N = 24)
Number of subjects: 72
Study 30797989 — intervention group
Group type: COMPARATOR
Intervention: No-Reminder control condition (N = 24)
Number of subjects: 72
Study 25751123 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-focused group intervention
Number of subjects: 134
Study 25751123 — intervention group
Group type: EXPERIMENTAL
Intervention: Common factors community-based group intervention
Number of subjects: 134
Study 25751123 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-specific factors in child sessions
Number of subjects: 134
Study 25751123 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific treatment factors in child and parent sessions
Number of subjects: 134
Study 25751123 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific treatment factors in parent intervention
Number of subjects: 134
Study 25751123 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-specific factors in intervention
Number of subjects: 134
Study 26089386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 810
Study 26089386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 810
Study 26089386 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 810
Study 22903789 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless mPCNL (ureteric catheter but no drainage tubes)
Number of subjects: 32
Study 22903789 — intervention group
Group type: COMPARATOR
Intervention: Conventional mPCNL (ureteric Double‐J stents and nephrostomy drainage tubes)
Number of subjects: 32
Study 21889137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual observation by colonoscopist and endoscopy nurse
Number of subjects: 844
Study 21889137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual observation by colonoscopist and endoscopy nurse with fellows (<500 colonoscopies)
Number of subjects: 844
Study 21889137 — intervention group
Group type: COMPARATOR
Intervention: Single observation by colonoscopist alone
Number of subjects: 844
Study 19217168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 681
Study 19217168 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized psychotherapy for chronic depression
Number of subjects: 681
Study 19217168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nefazodone and psychotherapy
Number of subjects: 681
Study 19217168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 681
Study 17117692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.4 mgr/0.2 ml) applied in 150 patients for 5 minutes during surgery
Number of subjects: 200
Study 17117692 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 patients without mitomycin C)
Number of subjects: 200
Study 17117692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 200
Study 15001969 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL normal-strength orange juice
Number of subjects: 10
Study 15001969 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 11286609 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg maximum daily dose, given three times per day)
Number of subjects: 62
Study 11286609 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.8 mg maximum daily dose, given three times per day)
Number of subjects: 62
Study 9401844 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydrated Hemoccult II tests (HII group)
Number of subjects: 6367
Study 9401844 — intervention group
Group type: COMPARATOR
Intervention: Flexible videosigmoidoscopy (FS group)
Number of subjects: 6367
Study 9401844 — intervention group
Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy subgroup with HII tests
Number of subjects: 6367
Study 9401844 — intervention group
Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy
Number of subjects: 6367
Study 9401844 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydrated HII tests
Number of subjects: 6367
Study 8430057 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol CR/ZOK (95 mg metoprolol succinate)
Number of subjects: 18
Study 8430057 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol OROS (95 mg metoprolol fumarate)
Number of subjects: 18
Study 8430057 — intervention group
Group type: COMPARATOR
Intervention: immediate-release tablet (100 mg metoprolol tartrate)
Number of subjects: 18
Study 8430057 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol CR/ZOK and metoprolol OROS
Number of subjects: 18
Study 8430057 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol CR/ZOK
Number of subjects: 18
Study 31545155 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz stimulation group
Number of subjects: 30
Study 31545155 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz stimulation group
Number of subjects: 30
Study 31545155 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 28614194 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom physical activity lessons (two 10-min sessions per day, 5 days a week)
Number of subjects: 0
Study 28614194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no classroom PA lessons)
Number of subjects: 0
Study 28614194 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom physical activity lessons
Number of subjects: 0
Study 26034150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (optimized to 300 or 450 mg/day)
Number of subjects: 197
Study 26034150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 197
Study 26034150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 23824561 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial screening instrument
Number of subjects: 568
Study 23824561 — intervention group
Group type: EXPERIMENTAL
Intervention: Early referral for psychosocial treatment
Number of subjects: 568
Study 23824561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychosocial screening)
Number of subjects: 568
Study 21798429 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 5 mg/kg/day
Number of subjects: 111
Study 21798429 — intervention group
Group type: COMPARATOR
Intervention: Heparin/warfarin (started within 24 h of heparin lead-in; target INR: 2.0 to 3.0)
Number of subjects: 111
Study 21798429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ASA and heparin/warfarin
Number of subjects: 111
Study 19205162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for tinnitus, 8 weeks duration
Number of subjects: 65
Study 19205162 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 65
Study 16785057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopically assisted semiflexed anteroposterior (AP) radiographs
Number of subjects: 80
Study 16785057 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoroscopic fixed-flexion (FF) radiographs
Number of subjects: 80
Study 16785057 — intervention group
Group type: COMPARATOR
Intervention: Metatarsophalangeal (MTP) radiographs
Number of subjects: 80
Study 16785057 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired radiographs with parallel or near-parallel alignment
Number of subjects: 80
Study 14616414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily with voriconazole 200 mg twice daily
Number of subjects: 12
Study 14616414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily with voriconazole 200 mg twice daily
Number of subjects: 12
Study 14616414 — intervention group
Group type: COMPARATOR
Intervention: Placebo with voriconazole 200 mg twice daily
Number of subjects: 12
Study 10800240 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation sedation
Number of subjects: 101
Study 10800240 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 101
Study 8833544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (10 mg)
Number of subjects: 17
Study 8833544 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden lactate (4 mg)
Number of subjects: 17
Study 8833544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1596550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangan‐DPDP (5 or 10 mumol/kg)
Number of subjects: 19
Study 3883170 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride, 60 mmol per day for six weeks
Number of subjects: 16
Study 3883170 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for six weeks
Number of subjects: 16
Study 31305464 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist (GLP-1RA) treatment for 6 months
Number of subjects: 164
Study 31305464 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of healthy individuals)
Number of subjects: 164
Study 29361042 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine (ALC) 1000 mg three times a day for 24 weeks
Number of subjects: 409
Study 29361042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 26304771 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐SOC
Number of subjects: 101
Study 26304771 — intervention group
Group type: COMPARATOR
Intervention: MS
Number of subjects: 101
Study 24885489 — intervention group
Group type: EXPERIMENTAL
Intervention: GPS location services
Number of subjects: 12
Study 22801564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (n=19)
Number of subjects: 37
Study 22801564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus fenofibrate (n=18)
Number of subjects: 37
Study 20630162 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment (3 x 24-hour dietary recalls)
Number of subjects: 135
Study 20630162 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment for 2-3 year olds
Number of subjects: 135